Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORLIGHT: ACP-211 in Treatment-Resistant Depression
NCT07284667Phase 2Recruiting
- Sponsor
- Acadia Pharmaceuticals
- Start
- Nov 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ACP-211 in treatment-resistant depression (TRD), sponsored by Acadia Pharmaceuticals. Started Nov 2025; status: recruiting.
02
Drugs
ACP-211
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT07284667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284667.